Home | Business News | Browse by Publication | P | PR Newswire

New Data Demonstrate That BENICAR(R) and BENICAR HCT(R) Significantly Reduces Systolic Hypertension, Which Allows Patients to Reach Aggressive Blood Pressure Goals.

Article Excerpt
Mean Blood Pressure Drops of 35 mm Hg* in Systolic Hypertensive Patients Presented at the American Society of Hypertension's Twentieth Annual Scientific Meeting (ASH 2005)

PARSIPPANY, N.J., May 27 /PRNewswire/ -- Data from two clinical studies presented at the American Society of Hypertension's Twentieth Annual Scientific Meeting (ASH 2005) in San Francisco demonstrated that BENICAR(R) (olmesartan medoxomil) and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) were effective in treating the difficult patient with Stage 2** hypertension, as well as the less complicated Stage 1** patient, helping both achieve nationally recognized blood pressure goals.

The first presentation, titled BENICAR Efficacy in Systolic Hypertension Trial (BEST), demonstrated that a BENICAR based treatment algorithm significantly reduced mean systolic blood pressure in a stage 2 systolic hypertensive population(1). Results demonstrated that BENICAR HCT (BENICAR 40 mg/25mg HCTZ once daily) decreased the systolic blood pressure level by approximately 35 mm Hg on average, resulting in 70% of patients who had a mean baseline blood pressure of 171/95 mm Hg reaching the blood pressure goal of less than 140/90 mm Hg.

The second presentation, titled Treatment of Stage 1 and Stage 2 Hypertension Utilizing An Olmesartan Medoxomil-Based Treatment Algorithm was a secondary analysis of data based on an earlier study evaluating BENICAR(2). This analysis demonstrated that a BENICAR based treatment algorithm was effective in helping Stage 1 and Stage 2 patients reach their blood pressure goal. In Stage 1 patients, 89% of the eligible patient cohort taking BENICAR or BENICAR HCT reached the more aggressive blood pressure goal of less than or equal to 130/85 mm Hg. Of the total Stage 1 patients, 56% reached goal on BENICAR monotherapy alone. Of the total Stage 2 patients, more than half (54%) reached goal on BENICAR or BENICAR HCT.

"I believe that blood pressure reduction to goal or better...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!